tiprankstipranks
Trending News
More News >
Prophase Labs (PRPH)
NASDAQ:PRPH
US Market
Advertisement

Prophase Labs (PRPH) Earnings Dates, Call Summary & Reports

Compare
313 Followers

Earnings Data

Report Date
Apr 01, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
Last Year’s EPS
-0.13
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 19, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call highlighted several promising developments, such as the Crown Medical collections, potential partnerships for the esophageal cancer test, and a turnaround in the Nebula Genomics business. However, these positives were counterbalanced by significant challenges, including financial constraints, a declining stock price, and the need for a reverse stock split to maintain Nasdaq compliance. The company is actively pursuing strategic initiatives to address these issues and improve shareholder value.
Company Guidance
During the ProPhase Labs, Inc.'s third-quarter 2025 earnings call, Chairman and CEO Ted Karkus provided several metrics and strategic insights. He emphasized the importance of shareholder voting on a critical proxy, which could impact strategic initiatives. The company is targeting collections of around $150 million in uncollected COVID testing claims, with expectations to net at least $50 million after discounts and fees. Karkus also discussed the potential of the BSmart esophageal cancer test, estimating a target market of $7-14 billion, and highlighted Nebula Genomics' restructuring towards profitability. ProPhase Labs' current market cap stands at approximately $12 million, with 46.1 million shares outstanding. Karkus addressed the possibility of a reverse stock split to maintain Nasdaq compliance, aiming to capitalize on the company's undervalued stock and significant asset potential.
Crown Medical Collections Initiative
Crown Medical has been appointed special counsel to collect $150 million in uncollected COVID testing claims. They expect to collect at least $50 million net, which could significantly improve the company's financial situation.
B Smart Esophageal Cancer Test
The esophageal cancer test is considered one of the best diagnostic tests for one of the deadliest cancers. Now that it's been published in a major journal, it has attracted interest from various companies looking to partner or acquire.
Nebula Genomics Business Turnaround
The Nebula Genomics business has been restructured to become primarily direct-to-consumer, with a subscription model that is profitable on a pro forma basis.
Potential Strategic Initiatives
The company is exploring multiple strategic initiatives, including potential M&A deals and partnerships, which could significantly enhance shareholder value. They are also considering a crypto treasury strategy once cash flow improves.

Prophase Labs (PRPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PRPH Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 01, 2026
2025 (Q4)
- / -
-0.13
Nov 19, 2025
2025 (Q3)
- / -0.16
-0.3554.29% (+0.19)
Aug 13, 2025
2025 (Q2)
-0.15 / -0.11
-0.3366.67% (+0.22)
May 20, 2025
2025 (Q1)
- / -0.13
-0.07-85.71% (-0.06)
Mar 31, 2025
2024 (Q4)
-0.18 / -0.13
-0.07-85.71% (-0.06)
Nov 13, 2024
2024 (Q3)
-0.31 / -0.35
-0.3-16.67% (-0.05)
Aug 14, 2024
2024 (Q2)
-0.08 / -0.33
-0.2-65.00% (-0.13)
May 09, 2024
2024 (Q1)
-0.28 / -0.07
0.03-333.33% (-0.10)
Mar 15, 2024
2023 (Q4)
-0.26 / -0.51
-0.15-240.00% (-0.36)
Nov 09, 2023
2023 (Q3)
-0.20 / -0.30
0.06-600.00% (-0.36)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PRPH Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 19, 2025
$0.26$0.23-11.54%
Aug 13, 2025
$0.35$0.33-5.71%
May 20, 2025
$0.32$0.33+3.13%
Mar 31, 2025
$0.44$0.40-9.09%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Prophase Labs (PRPH) report earnings?
Prophase Labs (PRPH) is schdueled to report earning on Apr 01, 2026, TBA (Confirmed).
    What is Prophase Labs (PRPH) earnings time?
    Prophase Labs (PRPH) earnings time is at Apr 01, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PRPH EPS forecast?
          Currently, no data Available
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis